Login
Novavax NASDAQ: NVAX
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants
| Name | Novavax |
| Ticker | NVAX |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Price | 131.46 |
| 52W Low/High | 6.31 / 178.51 |
| Market cap | 8.1 B |
| 1Y Total Return |
1,585.38%
Strong |
| 1Y Volatility |
138.38%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants
Details
| Ticker | NVAX |
| Name | Novavax |
| ISIN | US6700024010 |
| CUSIP | 670002401 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 1/25/21
| Close Price | 131.46 |
| 52W Low/High | 6.31 / 178.51 |
| Market cap | 8.1 B |
| 1Y Total Return |
1,585.38%
Strong |
| 1Y Volatility |
138.38%
High Risk |
| Beta | 1.51 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -133.1% |
| Cash from Op. / Cur. Liabilities | 0.26 |
| Diluted Earnings / Share | -5.17 |
| ROE | - |
| ROIC | -139.2% |
| Price / Revenue | 39.5 |
| Price / Book | 76.0 |
| Price / CF | 129.9 |
| Current Ratio | 2.8 |
| Cur.Liabilities / Tot.Liabilities | 0.4 |
| Financial Leverage | 4.14 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
205
|
16
|
39
|
26
|
16
|
37
|
|
| Gross Profit |
205
|
16
|
39
|
26
|
16
|
49
|
|
| R&D |
375
|
128
|
180
|
170
|
263
|
132
|
|
| EBITDA |
-254
|
-130
|
-164
|
-166
|
-284
|
-104
|
|
| Operating Income |
-263
|
-138
|
-175
|
-178
|
-294
|
-110
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
62
|
24
|
19
|
15
|
14
|
13
|
|
| EPS exc. Extra |
-5.17
|
-7.11
|
-10.66
|
-13.60
|
-22.40
|
-8.80
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
944
|
165
|
250
|
334
|
460
|
405
|
|
| Cash, Eq & Invt ShortTerm |
572
|
76
|
146
|
213
|
334
|
290
|
|
| Total Current Assets |
671
|
89
|
161
|
226
|
354
|
310
|
|
| Total Non-Current Assets |
273
|
76
|
90
|
108
|
106
|
95
|
|
| Intangibles |
132
|
56
|
59
|
62
|
63
|
64
|
|
| Total Liabilities |
638
|
355
|
377
|
408
|
410
|
38
|
|
| Total Current Liabilities |
239
|
22
|
47
|
68
|
76
|
25
|
|
| Long Term Debt |
399
|
333
|
330
|
340
|
334
|
13
|
|
| Shareholder equity |
106
|
-190
|
-127
|
-74
|
50
|
367
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
62
|
-158
|
-183
|
-166
|
-249
|
-91
|
|
| Depreciation |
4
|
7
|
8
|
10
|
8
|
6
|
|
| Cash from Investing |
-347
|
87
|
-3
|
105
|
-48
|
-13
|
|
| Capex |
13
|
2
|
2
|
7
|
20
|
16
|
|
| Cash from Financing |
610
|
72
|
116
|
48
|
279
|
208
|
|
| Stock Issued |
477
|
71
|
116
|
47
|
4
|
209
|
|
| Debt (LT) Issued |
-65
|
0
|
0
|
0
|
324
|
-1
|
|
| Free Cash Flow |
-273
|
-82
|
-192
|
-70
|
-273
|
-120
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
2.8
|
4.1
|
3.4
|
3.3
|
4.7
|
12.5
|
|
| Financial Leverage D/E |
4.14
|
-
|
-
|
-
|
6.35
|
0.00
|
|
| Return on Capital Avg |
-139.2%
|
-139.4%
|
-138.1%
|
-100.0%
|
-123.7%
|
-45.6%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available